A 48-Year-Old Man With Recurrent Nasopharyngeal Carcinoma and a 53-Year-Old Woman With Metastatic Nasopharyngeal Carcinoma : Episode 3

Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology

March 14, 2025

By Shravan Kandula, MD

Opinion

Video

An expert discusses the treatment approach for recurrence in Case 1, evaluating the combination of toripalimab + gemcitabine/cisplatin for recurrent disease and considering the potential for re-irradiation, while also reflecting on the treatment strategy in Case 2 and the criteria for determining whether the patient would benefit from additional radiation therapy.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Introduction to Clinical Cases: Toripalimab in Recurrent and Metastatic NPC

EP: 2.Considerations for NPC Therapy: Clinical Perspectives From Radiation Oncology

Now Viewing

EP: 3.Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology

EP: 4.Monitoring Treatment Response in NPC: Looking to EBV Titers and Imaging

EP: 5.Evolving Paradigms: The Role of Systemic Immunotherapy in NPC Treatment

Video content above is prompted by the following:

Please comment on the treatment approach for recurrence in Case 1.
What are your thoughts on toripalimab + gemcitabine/cisplatin for recurrent disease?
Would you consider re-irradiation in this patient?
What are your thoughts on the treatment approach in Case 2?
How do you determine whether the patient would benefit from the addition of radiation therapy?

Stay up to date on practice-changing data in community practice.

Subscribe Now!

Recent Videos